AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8105778
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment with cognitive therapy followed by exposure in vivo
Trial: 8105778
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (cognitive-behavioral treatment)
Trial: 3802928
Drug: Diltiazem (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.2, 0.3, and 0.4 mg/kg body weight, followed by infusion of 2, 3, and 4 micrograms/kg/min)
Trial: 31695323
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 µg/kg/h)
Trial: 26611473
Drug: Rituximab added
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab added to fludarabine and cyclophosphamide chemotherapy
Trial: 20399952
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (200 mcg every 6 hours after initial 400 mcg vaginally)
Trial: 20399952
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (initial 400 mcg, then 200 mcg every 6 hours)
Trial: 17613583
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium/vitamin D supplements and exercise/protein
Trial: 12844328
Drug: Subcutaneous melagatran
RxNorm normalized name: melagatran
DrugBank: Melagatran (DB13616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous melagatran
Trial: 12844328
Drug: Individualised dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised dosage based on creatinine clearance or bodyweight
Trial: 11095442
Drug: Alendronate treatment
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate treatment for 3-4 years
Trial: 8720425
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg extended-release (ER)
Trial: 1304448
Drug: Moclobemide 150
RxNorm normalized name: moclobemide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 150 mg t.i.d.
Trial: 3113974
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone releasing factor (hGRF-44 NH2) administered intravenously at doses of 2.5-80 micrograms, 80-320 micrograms, and 75-600 micrograms
Trial: 31219706
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with a median dose of 42 Gy/6 fractions (range 25 - 54 Gy/6#)
Trial: 19485591
Drug: Education support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education support treatment
Trial: 15590533
Drug: Anticoagulant/antiaggregating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant/antiaggregating agents
Trial: 15590533
Drug: Fibrinolytic/thrombolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic/thrombolytic agents
Trial: 8173688
Drug: Felodipine-Metoprolol combination
RxNorm normalized name: felodipine / metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-Metoprolol combination tablet
Trial: 30355865
Drug: Aurolab aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurolab aqueous drainage implant (AADI)
Trial: 24025111
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 500 mg daily (or 400 mg daily by intravenous infusion) for 7 days
Trial: 22858044
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine 10 mL and morphine 1.5mg (Group B+Mor)
Trial: 22858044
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine 10 mL and magnesium 500 mg (Group B+Mg)
Trial: 22858044
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine 10 mL morphine 1.5mg and magnesium 500 mg (Group B+Mor+Mg)
Trial: 22858044
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine 10 mL (Group B)
Trial: 20181257
Drug: Restrictive intraoperative
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive intraoperative intravenous fluid administration (Group A)
Trial: 20181257
Drug: Liberal intraoperative
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal intraoperative intravenous fluid administration (Group B)
Trial: 28555207
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant installation in fresh extraction sockets grafted with cortico‐cancellous heterologous bone and porcine derma (group A)
Trial: 28555207
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant installation 4 months after tooth extraction and socket preservation using the same materials (group B)
Trial: 28555207
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant installation (group A)
Trial: 28555207
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant installation (group B)
Trial: 10717755
Drug: Chloroquine 25
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 25 mg/kg and 14-days primaquine
Trial: 25270857
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 μg/kg bolus over 60 s followed by 0.05 μg/kg/min continuous infusion for 20 min)
Trial: 25270857
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% sodium chloride infusion at a volume and rate equal to that of remifentanil)
Trial: 20585896
Drug: Gain-framed message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gain-framed message (describing benefits of receiving the vaccine)
Trial: 20585896
Drug: Loss-framed message
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss-framed message (describing costs of not receiving the vaccine)
Trial: 16930145
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with a single dose of amoxicillin and clavulanic acid (group A, n = 193)
Trial: 15848701
Drug: Alemtuzumab induction
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab induction (30 mg IV intraoperatively) with rapid corticosteroid elimination
Trial: 15848701
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with alternate day rabbit antithymocyte globulin (rATG) induction with a steroid-based regimen
Trial: 10354696
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (T)
Trial: 8073235
Drug: Insurance supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insurance supplement for unconventional medicine (experimental group)
Trial: 8073235
Drug: Self-selected insurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected insurance supplement for unconventional medicine (third group)
Trial: 8073235
Drug: No coverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No coverage of unconventional medicine (control group)
Trial: 2645662
Drug: Top-up transfusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top-up transfusions to keep haemoglobin concentrations above 10 g/dl
Trial: 2645662
Drug: No transfusions,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No transfusions, allowing haemoglobin concentrations to fall below 10 g/dl
Trial: 29768301
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with bevacizumab (457 patients, 128 achieved pCR)
Trial: 29768301
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy without bevacizumab
Trial: 25482371
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 1500mg day(-1)
Trial: 25482371
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) 1800mg day(-1) + Metformin (MET) 1500mg day(-1)
Trial: 9275269
Drug: Prostate specific
RxNorm normalized name: Prostate specific antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate specific antigen prescreening followed by digital rectal examination, transrectal ultrasound, and biopsy if indicated.
Trial: 1773136
Drug: AHBuBP (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHBuBP (5 mg/day on two consecutive days every 3 months for one year)
Trial: 1773136
Drug: Calcium (oral)
RxNorm normalized name: calcium gluceptate Oral Solution
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (oral)
Trial: 30904830
Drug: Methotrexate administration
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate administration
Trial: 19685729
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of scalp-acupuncture, body-acupuncture, and abdominal-acupuncture
Trial: 31262398
Drug: Trazodone sustained-release
RxNorm normalized name: trazodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone sustained-release tablets (TSR)
Trial: 31262398
Drug: Trazodone immediate-release
RxNorm normalized name: trazodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone immediate-release formulation (TIR)
Trial: 31262398
Drug: Multiple dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosage of TSR and TIR
Trial: 7797125
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 micrograms, subcutaneously, three times daily)
Trial: 2152036
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol (group P)
Trial: 25814050
Drug: Solifenacin succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin succinate 5-10 mg daily
Trial: 21097688
Drug: Revalor‐X (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revalor‐X (200 mg of TBA and 40 mg of E(2))
Trial: 21097688
Drug: Revalor‐IS/S (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revalor‐IS/S (200 mg of TBA and 40 mg of E(2); reimplanted at 68 to 74 d)
Trial: 21097688
Drug: Revalor‐S (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revalor‐S (120 mg of TBA and 24 mg of E(2))
Trial: 334472
Drug: Flurbiprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (300 mg/day)
Trial: 334472
Drug: Aspirin (2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2.1 g/day)
Trial: 334472
Drug: Phenylbutazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (600 mg/day)
Trial: 28608601
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment for 8 weeks
Trial: 14699368
Drug: Localized high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Localized high-dose UVA1 irradiation
Trial: 14699368
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream psoralen-UVA (PUVA)
Trial: 9163613
Drug: Aspirin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (40 mg/d)
Trial: 3280157
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g bid, orally)
Trial: 3280157
Drug: L-carnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3 g as a bolus followed by an infusion of 2 mg/kg/min for 30 min, intravenously)
Trial: 23808255
Drug: Glutamine solution
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine solution intravenous use
Trial: 3517890
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pyritinol three times daily
Trial: 29102514
Drug: omalizumab 150
RxNorm normalized name: omalizumab 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omalizumab 150 mg
Trial: 25487196
Drug: Wood smoke
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood smoke exposure (1 mg/m³ particulate matter concentration)
Trial: 21838788
Drug: Adjusted dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dosing algorithm for HDMTX based on 24 h MTX plasma concentrations.
Trial: 21838788
Drug: Standard MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard MTX dose (not explicitly detailed in the abstract).
Trial: 21838788
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose (based on dosing algorithm).
Trial: 19961836
Drug: Amphetamine (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (an indirect DA agonist)
Trial: 19961836
Drug: Haloperidol (DA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (DA D2 receptor antagonist)
Trial: 15627855
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT-A) - 25 sessions
Trial: 15627855
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT-B) - after contact control period
Trial: 15627855
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT-A)
Trial: 15627855
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT-B)
Trial: 12798827
Drug: Revascularisation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularisation in addition to optimal medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists, anti-thrombotic agent)
Trial: 12798827
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists, anti-thrombotic agent) without revascularisation
Trial: 1833121
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg three times a day for 6 weeks)
Trial: 1833121
Drug: Acarbose (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (first treatment)
Trial: 1833121
Drug: Placebo (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (first treatment)
Trial: 1833121
Drug: Acarbose (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (second treatment)
Trial: 1833121
Drug: Placebo (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (second treatment)
Trial: 6341844
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg with meals and at bedtime)
Trial: 6341844
Drug: Antacid (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (15 ml one hour after meals and at bedtime)
Trial: 6341844
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and Antacid
Trial: 29119807
Drug: Beliefs About
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beliefs About Medication Scale (BAMS)
Trial: 22077915
Drug: Chemo‐mechanical preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo‐mechanical preparation with no medication
Trial: 22077915
Drug: No chemo‐mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemo‐mechanical preparation and no medication
Trial: 17255739
Drug: lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir (LPV/r) 533 mg/133 mg twice daily + efavirenz (EFV) 600 mg once daily
Trial: 17255739
Drug: EFV +
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EFV + two nucleoside reverse transcriptase inhibitors (NRTI)
Trial: 15963081
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg t.d.s. with Omeprazole
Trial: 1958158
Drug: Brief intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intensive group cognitive behavioural therapy (2 days)
Trial: 31690988
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg once daily for 26 weeks
Trial: 21333060
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (small-volume nebulizer or 1-hour continuous nebulization)
Trial: 19244376
Drug: Bread fortified
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving
Trial: 17132479
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including graft augmentation, site-specific repair, and posterior colporrhaphy)
Trial: 12767421
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg/ER niacin 2 g
Trial: 12767421
Drug: ER niacin
RxNorm normalized name: Leader Niacin 500mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER niacin 2 g
Trial: 12767421
Drug: rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 40 mg/ER niacin 1 g
Trial: 10650230
Drug: Diclofenac ophthalmic
RxNorm normalized name: diclofenac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac ophthalmic solution
Trial: 9579961
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg GBP oral dose in fasting state
Trial: 9579961
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg GBP oral dose in fasting state
Trial: 9579961
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg GBP oral dose after a high-protein meal
Trial: 9579961
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg GBP oral dose after a high-protein meal
Trial: 29049890
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly group-based health-related education sessions, 6 months duration, six 1-hour sessions)
Trial: 25904498
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% ointment (CP)
Trial: 25904498
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% ointment (MMF)
Trial: 22421983
Drug: GLP-1 treatment
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 treatment for 48 hours
Trial: 12826783
Drug: Amlodipine/benazepril 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/benazepril 5/10 mg (combination)
Trial: 12826783
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg (conventional)
Trial: 10982310
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg PGE1 plus 1 mg PHE
Trial: 1627943
Drug: Great-dose huanshao
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Great-dose huanshao dan capsules
Trial: 1627943
Drug: Great-dose watered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Great-dose watered pills
Trial: 1627943
Drug: Small-dose watered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose watered pills
Trial: 1627943
Drug: Huanshao dan
RxNorm normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huanshao dan and watered pills (combined)
Trial: 6370979
Drug: Nomifensine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (100 mg single daily dose)
Trial: 29941021
Drug: Fluralaner spot-on
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner spot-on treatment (Bravecto®) at a dose rate of 40 mg/kg, administered topically on Day 0.